Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04VJE
|
|||
| Former ID |
DNC007881
|
|||
| Drug Name |
6-(2-phenethylisoindolin-5-yloxy)nicotinamide
|
|||
| Synonyms |
CHEMBL235154; 6-(2-phenethylisoindolin-5-yloxy)nicotinamide; SCHEMBL3696847
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C22H21N3O2
|
|||
| Canonical SMILES |
C1C2=C(CN1CCC3=CC=CC=C3)C=C(C=C2)OC4=NC=C(C=C4)C(=O)N
|
|||
| InChI |
1S/C22H21N3O2/c23-22(26)17-7-9-21(24-13-17)27-20-8-6-18-14-25(15-19(18)12-20)11-10-16-4-2-1-3-5-16/h1-9,12-13H,10-11,14-15H2,(H2,23,26)
|
|||
| InChIKey |
ACAQNMZIFFSQCU-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Opioid receptor delta (OPRD1) | Target Info | Inhibitor | [1] |
| Opioid receptor mu (MOP) | Target Info | Inhibitor | [1] | |
| KEGG Pathway | cGMP-PKG signaling pathway | |||
| Sphingolipid signaling pathway | ||||
| Neuroactive ligand-receptor interaction | ||||
| Estrogen signaling pathway | ||||
| Morphine addiction | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
| Enkephalin release | ||||
| Opioid proenkephalin pathway | ||||
| Opioid proopiomelanocortin pathway | ||||
| Pathway Interaction Database | IL4-mediated signaling events | |||
| Reactome | Peptide ligand-binding receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Peptide GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| TCR Signaling Pathway | ||||
| Opioid Signalling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Structure activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 2. Bioorg Med Chem Lett. 2007 Dec 15;17(24):6841-6. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.